Overview
Our laboratory uses genomic and pharmacological approaches to understand how tumor dependencies are shaped by cell intrinsic factors, environmental factors, and drug treatments during the dynamic process of tumor evolution. To learn more, please visit our laboratory website: https://woodlabduke.com/.
Current Appointments & Affiliations
Professor of Pharmacology and Cancer Biology
·
2025 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Professor of Cell Biology
·
2025 - Present
Cell Biology,
Basic Science Departments
Member of the Duke Cancer Institute
·
2012 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge.
Journal Article Nat Commun · January 14, 2026 Targeted therapies have revolutionized cancer care. Unfortunately, most patients develop refractory, multifocal resistance to these therapies within a matter of months. Here, we demonstrate that the evolution of resistance to EGFR inhibitors in EGFR-mutant ... Full text Link to item CiteExploiting tumor lineage features for precision cancer therapy.
Journal Article Trends Cancer · January 2, 2026 Cancer cells often retain lineage- and tissue of origin-specific programs established prior to malignant transformation. This observation has been elaborated by advances in single-cell and lineage-tracing technologies, which provide high-resolution mapping ... Full text Link to item CitePathway coessentiality mapping reveals complex II is required for de novo purine biosynthesis in acute myeloid leukaemia.
Journal Article Nat Metab · December 2025 Understanding how cellular pathways interact is crucial for treating complex diseases like cancer. Individual gene-gene interaction studies have provided valuable insights, but may miss pathways working together. Here we develop a multi-gene approach to pa ... Full text Link to item CiteRecent Grants
Identification and targeting of essential regions of driver fusion oncoproteins in rhabdomyosarcoma
ResearchCo Investigator · Awarded by V Foundation for Cancer Research · 2025 - 2030Eradicating residual non-small cell lung cancers by targeting their PKN2-dependent survival
ResearchPrincipal Investigator · Awarded by V Foundation for Cancer Research · 2025 - 2030Pharmacological Sciences Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030View All Grants
Education, Training & Certifications
Massachusetts Institute of Technology ·
2007
Ph.D.